First-Line Therapy for Metastatic RCC Remains Controversial Amid New Approvals

Leggi l'articolo originale


The bar for the standard of care among patients with advanced renal cell carcinoma is set high as various promising combination therapies recently received FDA approval.

Lascia un commento